Histogenics (NASDAQ:HSGX) had its price objective boosted by Needham & Company LLC to $5.00 in a research report report published on Thursday, The Fly reports. Needham & Company LLC currently has a buy rating on the biotechnology company’s stock.
A number of other equities research analysts also recently weighed in on the company. HC Wainwright reaffirmed a buy rating and set a $3.50 price objective on shares of Histogenics in a report on Monday, August 13th. Zacks Investment Research downgraded Histogenics from a buy rating to a hold rating in a report on Thursday, August 16th. Brookline Cap M reaffirmed a buy rating on shares of Histogenics in a report on Wednesday, August 1st. ValuEngine downgraded Histogenics from a hold rating to a sell rating in a report on Thursday, May 17th. Finally, BTIG Research downgraded Histogenics from a buy rating to a neutral rating and set a $3.50 price objective on the stock. in a report on Wednesday. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $3.45.
NASDAQ HSGX traded up $0.01 during trading on Thursday, reaching $0.72. 20,568 shares of the company traded hands, compared to its average volume of 983,039. The company has a market capitalization of $22.22 million, a price-to-earnings ratio of -0.71 and a beta of 1.70. Histogenics has a 1-year low of $0.68 and a 1-year high of $3.35.
Histogenics (NASDAQ:HSGX) last released its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.10. equities analysts expect that Histogenics will post -0.71 EPS for the current year.
Several large investors have recently bought and sold shares of HSGX. Sofinnova Ventures Inc bought a new position in shares of Histogenics in the first quarter valued at approximately $5,712,000. Archon Capital Management LLC bought a new position in shares of Histogenics in the first quarter valued at approximately $639,000. JPMorgan Chase & Co. bought a new position in shares of Histogenics in the first quarter valued at approximately $320,000. DRW Securities LLC bought a new position in shares of Histogenics in the second quarter valued at approximately $242,000. Finally, Renaissance Technologies LLC raised its stake in shares of Histogenics by 54.8% in the fourth quarter. Renaissance Technologies LLC now owns 242,500 shares of the biotechnology company’s stock valued at $497,000 after acquiring an additional 85,800 shares during the last quarter. Institutional investors own 45.89% of the company’s stock.
Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Further Reading: Risk Tolerance
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.